Altimmune raises ~$75M in registered direct offering of common stock and pre-funded warrants

Altimmune, Inc.

Issued 12.4M shares and pre-funded warrants for 4.6M shares at $4.40/share; gross proceeds ~$75M.
Closing expected Jan 29, 2026; Titan Partners acted as sole placement agent.
Pre-funded warrants exercisable at $0.001, no expiration, 9.99% beneficial ownership limit.
Directors and officers subject to 30-day lock-up agreements with customary exceptions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Altimmune, Inc. entered into Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-01-27).

Action: entry
Agreement: underwriting
Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
Effective: 2026-01-27

Exact text from the filing

The Company also entered into a Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners”) (the “Placement Agency Agreement,” and together with the Securities Purchase Agreement, the “Agreements”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Altimmune, Inc. entered into Securities Purchase Agreement with a new fundamental institutional investor valued at approximately $75 million (effective 2026-01-27).

Action: entry
Agreement: equity purchase
Counterparty: a new fundamental institutional investor
Value: approximately $75 million
Effective: 2026-01-27

Exact text from the filing

On January 27, 2026, Altimmune, Inc. (the “Company”) entered into a Securities Purchase Agreement with a new fundamental institutional investor (the “Securities Purchase Agreement”) relating to the issuance of 12,397,920 shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”)

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-26-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.